Skip to main content
Liaoning Cheng Da Co.,Ltd. logo

Liaoning Cheng Da Co.,Ltd. — Investor Relations & Filings

Ticker · 600739 ISIN · CNE000000LY3 LEI · 300300ZCCWKNUJRL8D79 Shanghai Stock Exchange Financial and insurance activities
Open in API
Filings indexed 2,288 across all filing types
Latest filing 2024-12-31 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600739

About Liaoning Cheng Da Co.,Ltd.

https://en.chengda.com.cn/

Liaoning Cheng Da Co., Ltd. is a diversified conglomerate operating across several strategic sectors, including biopharmaceuticals, financial services, energy development, and international trade. The company is a prominent player in the biopharmaceutical field through its specialized subsidiaries, focusing on the research, development, and production of human vaccines, most notably its market-leading purified Vero cell rabies vaccine. In the energy sector, it engages in the extraction and processing of oil shale. Its financial services division involves significant investments in securities firms and insurance companies. Additionally, the company maintains a robust international trade business, dealing in commodities such as textiles and chemicals. Liaoning Cheng Da focuses on integrating industrial operations with financial capital to drive growth across its various business units.

Recent filings

Filing Released Lang Actions
辽宁成大股份有限公司关于开展远期售汇等外汇衍生品业务的可行性分析报告
Regulatory Filings Classification · 90% confidence The document is titled as a "Feasibility Analysis Report" regarding the company's plan to conduct forward foreign exchange sales and other foreign exchange derivative business. It discusses the purpose, basic situation, risk analysis, risk control measures, accounting principles, and concludes on the feasibility of the business. The document is a detailed internal analysis and risk assessment report rather than a financial statement, regulatory filing, or announcement. It does not contain financial results, earnings data, or voting information. It is not a certification or a brief announcement. It is a standalone report focused on the feasibility and risk management of a specific financial activity. Given the nature of the document, it best fits under the category of Regulatory Filings (RNS) as it is a regulatory disclosure about a financial activity but does not match other more specific categories like Capital/Financing Update or Audit Report. The document length is short (1631 characters), but it is a full report, not just an announcement of a report publication. Therefore, the classification is RNS with high confidence.
2024-12-31 Chinese
辽宁成大股份有限公司关于公司2025年度开展远期结汇等外汇衍生品业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 辽宁成大股份有限公司 regarding the company's plan to conduct forward foreign exchange settlement and other foreign exchange derivative business in 2025. It details the purpose, transaction amount, risk analysis, risk control measures, and the board's approval of the plan. The document is a formal announcement of a financing or capital risk management activity related to foreign exchange derivatives, not a financial report or earnings release. It does not contain financial statements or detailed financial results, nor is it a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it updates on the company's planned foreign exchange derivative transactions and related risk management for the upcoming fiscal year.
2024-12-31 Chinese
辽宁成大股份有限公司关于开展远期结汇等外汇衍生品业务的可行性分析报告
Management Reports Classification · 95% confidence The document is titled as a "Feasibility Analysis Report" regarding the company's plan to conduct forward foreign exchange settlement and other foreign exchange derivative businesses. It discusses the purpose, basic situation, risk analysis, risk control measures, accounting principles, and concludes on the feasibility of the business. The content is a detailed internal analysis and assessment rather than a financial report or announcement. It does not contain financial statements, earnings data, or regulatory filings. It is not an announcement of a report publication but a standalone feasibility report. This type of document does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is an internal management report analyzing a specific business activity and its risks and controls. Therefore, the best fitting category is Management Reports (MDA).
2024-12-31 Chinese
辽宁成大股份有限公司关于公司2025年度开展远期售汇等外汇衍生品业务的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Liaoning Chengda Co., Ltd. regarding the company's plan to conduct forward foreign exchange sales and other foreign exchange derivative businesses in 2025. It details the purpose, transaction amounts, risk analysis, risk control measures, and accounting treatment related to these derivative transactions. The document includes information about board approval and risk disclosures but does not contain actual financial statements or comprehensive financial performance data. It is a regulatory announcement about financing and risk management activities related to foreign exchange derivatives rather than a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and risk management related to foreign exchange derivatives.
2024-12-31 Chinese
辽宁成大股份有限公司关于公司2025年度开展商品期货业务的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 辽宁成大股份有限公司 regarding the company's plan to conduct commodity futures business in 2025. It details the purpose, transaction amounts, risk analysis, internal controls, and board approval of this new business activity. The document is relatively short (3128 characters) and does not contain financial statements or detailed financial performance data. It is a regulatory announcement about a new business activity and risk management measures, not a financial report or earnings release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a report publication announcement since it contains substantive information about the business plan and approvals. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-12-31 Chinese
辽宁成大股份有限公司第十届董事会第三十一次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 辽宁成大股份有限公司. It details the date of the meeting, attendance, and voting results on specific business proposals for 2025. The content focuses on board decisions and approvals rather than financial results, audit opinions, or shareholder voting outcomes. There is no indication that this is a full annual report, audit report, or earnings release. The document is not a proxy solicitation or AGM materials but rather a board meeting resolution announcement. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length and content support this classification with high confidence.
2024-12-31 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.